These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25755604)

  • 1. Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma.
    Arora A; Kumar A
    J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S126-9. PubMed ID: 25755604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
    Liu Q; Li A; Sun S; Luo R; Chen F
    J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.
    Shim JH; Lee HC; Kim SO; Shin YM; Kim KM; Lim YS; Suh DJ
    Radiology; 2012 Feb; 262(2):708-18. PubMed ID: 22187634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
    Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
    Zhang W; Xu AH; Wang W; Wu YH; Sun QL; Shu C
    BMC Cancer; 2019 Nov; 19(1):1041. PubMed ID: 31690274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
    Kim MN; Kim BK; Han KH; Kim SU
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):335-48. PubMed ID: 25370168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of liver tumour response by imaging.
    Gregory J; Dioguardi Burgio M; Corrias G; Vilgrain V; Ronot M
    JHEP Rep; 2020 Jun; 2(3):100100. PubMed ID: 32514496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies.
    Lewis HL; Ghasabeh MA; Khoshpouri P; Kamel IR; Pawlik TM
    Surg Oncol; 2017 Dec; 26(4):411-422. PubMed ID: 29113660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.